Novavax News

Novavax | 8-K: Novavax Announces Changes to Board of Directors

Mar 11 16:46 ET

Novavax | 8-K: Novavax Pharmaceuticals Announces Termination of Avance Holdings Purchase Agreement with the Government of Canada on March 7, 2025

Mar 11 08:30 ET

Novavax | 8-K: Investor Presentation

Mar 4 08:02 ET

Novavax | 8-K: Investor Presentation

Jan 13 07:52 ET

Novavax | 8-K: Asset Purchase Agreement

Dec 30, 2024 17:30 ET

Novavax | 8-K: Amendment No. 5 to the Advance Purchase Agreement

Dec 18, 2024 17:29 ET

Novavax | 8-K: Asset Purchase Agreement

Dec 4, 2024 06:07 ET

Novavax | 8-K: Investor Presentation

Nov 20, 2024 12:57 ET

Novavax | 8-K: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Nov 12, 2024 11:24 ET

Novavax | 8-K: Settlement Agreement

Nov 5, 2024 17:06 ET

Novavax | 8-K: Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Oct 16, 2024 08:02 ET

Novavax | 8-K: Regulation FD Disclosure

Oct 3, 2024 14:51 ET

Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Aug 8, 2024 16:21 ET

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

Jun 14, 2024 16:07 ET

Novavax | 8-K: Investor Presentation of Novavax, Inc.

Jun 6, 2024 07:01 ET

Novavax | DEFA14A: Others

Jun 5, 2024 06:06 ET

Novavax | 8-K: R&D President Filip Dubovsky Resigns

May 23, 2024 16:12 ET

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 20, 2024 14:45 ET

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 13, 2024 16:15 ET

Novavax | 8-K: Collaboration and License Agreement

May 13, 2024 14:44 ET